KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) EBITDA (2016 - 2025)

Historic EBITDA for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $825.0 million.

  • Boston Scientific's EBITDA rose 2222.22% to $825.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 billion, marking a year-over-year increase of 3880.14%. This contributed to the annual value of $3.6 billion for FY2025, which is 3880.14% up from last year.
  • Latest data reveals that Boston Scientific reported EBITDA of $825.0 million as of Q4 2025, which was up 2222.22% from $1.0 billion recorded in Q3 2025.
  • In the past 5 years, Boston Scientific's EBITDA registered a high of $1.0 billion during Q3 2025, and its lowest value of $180.0 million during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was $536.0 million (2023), whereas its average is $570.4 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 46901.41% in 2021, then plummeted by 749.35% in 2022.
  • Boston Scientific's EBITDA (Quarter) stood at $180.0 million in 2021, then skyrocketed by 123.33% to $402.0 million in 2022, then surged by 45.27% to $584.0 million in 2023, then increased by 15.58% to $675.0 million in 2024, then increased by 22.22% to $825.0 million in 2025.
  • Its last three reported values are $825.0 million in Q4 2025, $1.0 billion for Q3 2025, and $819.0 million during Q2 2025.